gimli
SUNPHARMA stock analysis context
SUN PHARMACEUTICAL IND L Stock Context for AI Screening
SUN PHARMACEUTICAL IND L is a large-cap stock in Healthcare. This page summarizes key screening signals for SUN PHARMACEUTICAL IND L, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Ask Gimli about SUNPHARMAPrice
₹1,844.60
1M return
+10.47%
3M return
+6.97%
Market cap
₹442,581.33 cr
PE
41.36
ROE
+15.33%
RSI
54.74
Turnover
₹666.04 cr
Why it can matter in screens
- Momentum: SUNPHARMA is above 50DMA, above 200DMA; RSI is 54.74.
- Returns: 1M +10.47%, 3M +6.97%, 6M +3.65%.
- Liquidity: latest turnover is ₹666.04 cr.
- Valuation: PE 41.36, PB n/a, ROE +15.33%, ROCE +19.81%.
- Growth: 3Y sales CAGR +10.64%, 3Y profit CAGR +49.46%.
Try these prompts
- Analyze SUN PHARMACEUTICAL IND L with valuation, momentum and industry peers
- Compare SUNPHARMA with other Healthcare stocks
- Show large-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View large-cap stocks
- Find stocks above 50DMA
- Compare SUNPHARMA with other Healthcare stocks
Data snapshot: 2026-05-22. Not investment advice.